Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
The antibody was designed and developed at Abzena’s Cambridge, UK,
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Cagrilintide represents a novel approach to obesity management
Subscribe To Our Newsletter & Stay Updated
